The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation

Aim. To study the efficacy and safety of the use of paritaprevir, ritonavir, ombitasvir and dasabuvir in combination or without ribavirin in liver recipients with recurrence of HCV 1 genotype after transplantation.

Materials and methods. The study included 46 patients after orthotopic liver transplantation with recurrence of HCV 1 genotype. 37 patients completed a 24-week course of antiviral therapy, including paritaprevir, ritonavir, ombitasvir and dasabuvir in combination or without ribavirin. The effectiveness of the therapy was calculated as the proportion of patients who achieved aviremia 12 weeks after the end of the course of treatment. The safety of therapy was assessed by the number of adverse events that occurred during the course of antiviral therapy.

Results. A sustained virologic response at 12 weeks after the end of the course of antiviral therapy, including paritaprevir, ritonavir, ombitasvir and dasabuvir, reached 100% of the recipients of the liver. Reduction in the intensity of cytolytic and cholestatic syndromes was noted at week 4 of therapy. Adverse events were recorded in 56.7% of the subjects, mostly they were not severe and were stopped on their own. Acute cellular rejection of the transplant developed in 1 patient (2.7%). There have been no cases of irreversible liver transplant dysfunction or death of the recipient.

The conclusion. The use of paritaprevir, ritonavir, ombitasvir and dasabuvir is safe and effective in the treatment of relapse of HCV infection of 1 genotype after liver transplantation.

1. Klempnauer J, Castaing D, Neuhaus P et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57: 675–688.

2. Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010; 10: 1003–1019.

3. Firpi RJ, Clark V, Soldevila­Pico C, Morelli G, Cabrera R, Levy C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009; 15: 1063–1071.

4. Forman LM, Lewis JD, Berlin JA et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterol. 2002; 122: 889–96.

5. Selzner N, Renner E, Selzner M et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009; 88: 1214–1221.

6. Veldt BJ, Poterucha JJ, Watt KD et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008; 8: 2426–2433.

7. Carrión JA, Navasa M, García­Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterol. 2007; 132: 1746–1756.

8. Kwo PY, Mantry PS, Coakley E et al. An interferonfree antiviral regimen for HCV after liver transplantation. The New England Journal of Medicine. 2014; 371: 2375–2382.

9. Yu ML, Chen YL, Huang CF et al. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. Journal of the Formosan Medical Association. 2018; 117: 518–526.

10. Tronina O, Durlik M, Wawrzynowicz­Syczewska M, Buivydiene A, Katzarov K, Kupcinskas L et. al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV). Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBERCEE Study. Ann Transplant. 2017; 22:199–207. doi: 10.12659/AOT.903535.

11. Yu ML, Liu CH, Huang CF et al. Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. PlOS One. 2012; 7: 520.

12. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142: 1373–1383.

13. Zimmermann T, Bocher WO, Biesterfeld S et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007; 20: 583–590.

14. Wang CS, Ko HH, Yoshida EM et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006; 6: 1586–1599.

15. Jain A, Sharma R, Ryan C et al. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clin Transpl. 2010; 24: 104–111.

16. Gonzalez SA. Management of recurrent hepatitis C following liver transplantation. Gastroenterol & Hepatol. 2010; 6: 637–645.

17. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008; 14: 58–66.

18. Aragwal K, Castells L, Müllhaupt B et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. J of Hepatol. 2017; 6: 34–46.

19. Poordad F, Schiff ER, Vierling JM et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatol. 2016; 63: 1493–1505.

20. Бакулин ИГ, Сандлер ЮГ, Шарабанов АС. Гематологические нежелательные явления при проведении противовирусной терапии у больных хроническим гепатитом С. Гепатологический форум. 2011; 4: 2–14. Bakulin IG, Sandler JuG, Sharabanov AS. Gematologicheskie nezhelatel’nye javlenija pri provedenii protivovirusnoj terapii u bol’nyh hronicheskim gepatitom S. Gepatologicheskij forum. 2011; 4: 2–14.

21. Моисеев СВ, Абдурахманов ДТ. Применение кроветворных факторов роста для улучшения результатов противовирусной терапии у пациентов с хроническим гепатитом С. Клиническая гепатология. 2011; 7 (2): 39–43. Moiseev SV, Abdurahmanov DT. Primenenie krovetvornyh faktorov rosta dlja uluchshenija rezul’tatov protivovirusnoj terapii u pacientov s hronicheskim gepatitom S. Klinicheskaja gepatologija. 2011: 7 (2): 39–43.

22. Afdhal N, Dieterich D, Pockros P et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004; 126: 1302–1311.

23. Sulkowski М, Wаssеrman R, Brooks L. Changes in haemoglobin during interferon аlрhа-2b plus ribavirin combination therapy for chronic hepatitis С virus infection. J Viral Hepatol. 2004; 11: 243–250.

24. Toyoda H, Kumada T. Pharmacotherapy of chronic hepatitis C virus infection – the IDEAL trial: ‘2b or not 2b (=2a), that is the question’. Expert Opinion on Pharmacotherapy. 2009; 17: 2845–2857.

25. Coilly A, Fougerou­Leurent C, de Ledinghen V et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – the ANRS CUPILT study. J of Hepatol. 2016; 65: 711–718.

26. Pockros PJ, Reddy KR, Mantry PS et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016; 150: 1590–1598.